134 related articles for article (PubMed ID: 25983263)
21. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Liao BC; Lin CC; Yang JC
Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
[TBL] [Abstract][Full Text] [Related]
22. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
[TBL] [Abstract][Full Text] [Related]
23. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
[TBL] [Abstract][Full Text] [Related]
24. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations.
Wang Z; Shen Z; Li Z; Duan J; Fu S; Liu Z; Bai H; Zhang Z; Zhao J; Wang X; Wang J
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):9990-5. PubMed ID: 26216950
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Ahmed SM; Salgia R
Respirology; 2006 Nov; 11(6):687-92. PubMed ID: 17052295
[TBL] [Abstract][Full Text] [Related]
26. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
Haber DA; Bell DW; Sordella R; Kwak EL; Godin-Heymann N; Sharma SV; Lynch TJ; Settleman J
Cold Spring Harb Symp Quant Biol; 2005; 70():419-26. PubMed ID: 16869779
[TBL] [Abstract][Full Text] [Related]
27. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.
Suda K; Mizuuchi H; Sato K; Takemoto T; Iwasaki T; Mitsudomi T
Int J Cancer; 2014 Aug; 135(4):1002-6. PubMed ID: 24458568
[TBL] [Abstract][Full Text] [Related]
28. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
[TBL] [Abstract][Full Text] [Related]
29. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
Zhang WQ; Li T; Li H
Med Sci Monit; 2014 Dec; 20():2666-76. PubMed ID: 25503781
[TBL] [Abstract][Full Text] [Related]
31. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
33. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
34. Lung cancer in 'never-smokers': beyond EGFR mutations and EGFR-TK inhibitors.
Burns TF; Rudin CM
Oncology (Williston Park); 2010 Jan; 24(1):48-9. PubMed ID: 20187321
[No Abstract] [Full Text] [Related]
35. Development of personalized treatments in lung cancer: focusing on the
Suda K; Mitsudomi T
Lung Cancer (Auckl); 2013; 4():43-53. PubMed ID: 28210134
[TBL] [Abstract][Full Text] [Related]
36. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors.
Weber F; Fukino K; Sawada T; Williams N; Sweet K; Brena RM; Plass C; Caldes T; Mutter GL; Villalona-Calero MA; Eng C
Br J Cancer; 2005 May; 92(10):1922-6. PubMed ID: 15841079
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor mutation and chemosensitivity.
Matsubara D; Niki T
J Thorac Oncol; 2012 Apr; 7(4):771-2; author reply 772-773. PubMed ID: 22425932
[No Abstract] [Full Text] [Related]
38. [Pharmacological consequences of the targeting of epidermal growth factor receptor].
Milano G; Magné N
Bull Cancer; 2003 Nov; 90 Spec No():S197-201. PubMed ID: 14763140
[TBL] [Abstract][Full Text] [Related]
39. [Molecular biology in diagnosis and treatment of lung cancer].
Mitsudomi T
Kyobu Geka; 2007 May; 60(5):349-54. PubMed ID: 17515077
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of EGFR signaling: all mutations are not created equal.
Gazdar AF; Minna JD
PLoS Med; 2005 Nov; 2(11):e377. PubMed ID: 16288556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
